Detection of SARS-CoV-2 Neutralizing Antibodies and Vaccine Development
The development and deployment of safe, effective, affordable, and accessible vaccines are essential for reducing transmission and disease severity. A central component of vaccine evaluation and immune protection against SARS-CoV-2 is the measurement of neutralizing antibodies, which serve as key in...
Saved in:
| 格式: | Online |
|---|---|
| 語言: | 英语 |
| 出版: |
MDPI - Multidisciplinary Digital Publishing Institute
2026
|
| 主題: | |
| 在線閱讀: | ONIX_20260416T142754_9783725865345_24 |
| 標簽: |
沒有標簽, 成為第一個標記此記錄!
|
| _version_ | 1869526426196115456 |
|---|---|
| collection | Directory of Open Access Books |
| description | The development and deployment of safe, effective, affordable, and accessible vaccines are essential for reducing transmission and disease severity. A central component of vaccine evaluation and immune protection against SARS-CoV-2 is the measurement of neutralizing antibodies, which serve as key indicators of antiviral immune activity. Accordingly, there is an urgent need for standardized, reliable, and reproducible in vitro potency assays to assess antiviral products throughout preclinical and clinical development. Neutralizing antibody assays are critical not only for evaluating vaccine efficacy but also for characterizing immune responses in COVID-19 patients, asymptomatic individuals, and vaccinated populations. However, current SARS-CoV-2 neutralization assays—including live virus, recombinant virus, pseudotyped virus, and competition-based assays—exhibit substantial methodological diversity. Differences in protocols, reagents, and result interpretation across laboratories have led to significant variability, limiting comparability between studies and vaccines and hindering the establishment of robust correlates of protection. This reprint provides a systematic and up-to-date overview of advances in SARS-CoV-2 neutralization assay development and vaccine evaluation. By summarizing methodological progress and remaining challenges, it aims to serve as a reference for researchers, clinicians, regulatory scientists, and public health professionals involved in COVID-19 research and response. |
| format | Online |
| id | doab-20.500.12854ir-175369 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2026 |
| publishDateRange | 2026 |
| publishDateSort | 2026 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1753692026-04-16T20:30:35Z Detection of SARS-CoV-2 Neutralizing Antibodies and Vaccine Development Nie, Jianhui SARS-CoV-2 Neutralising antibodies Point-of-care diagnostic test Antiviral Monoclonal antibody Cytokine blockers Correlates of protection Antibody dynamics Antibody kinetics Anti-SARS-CoV-2 antibodies Longitudinal assessment Serological immune response Humoral response post-vaccination Vaccination breakthrough Side effects Vaccination strategy COVID-19 Omicron Breakthrough infection Booster vaccination Primary vaccination Spike Standardization LC–MS Vaccine SARS-CoV-2 pseudovirus Mouse model In vivo bioluminescent DNA vaccine Epitope mapping Microarray Neutralizing antibodies Inactivated vaccines Delta Immunogenicity Adjuvants Bivalent vaccination Neutralization Assay Surrogate Antibodies High-content screening Variants Clinical trials Standards Correlation of protection N A thema EDItEUR::M Medicine and Nursing The development and deployment of safe, effective, affordable, and accessible vaccines are essential for reducing transmission and disease severity. A central component of vaccine evaluation and immune protection against SARS-CoV-2 is the measurement of neutralizing antibodies, which serve as key indicators of antiviral immune activity. Accordingly, there is an urgent need for standardized, reliable, and reproducible in vitro potency assays to assess antiviral products throughout preclinical and clinical development. Neutralizing antibody assays are critical not only for evaluating vaccine efficacy but also for characterizing immune responses in COVID-19 patients, asymptomatic individuals, and vaccinated populations. However, current SARS-CoV-2 neutralization assays—including live virus, recombinant virus, pseudotyped virus, and competition-based assays—exhibit substantial methodological diversity. Differences in protocols, reagents, and result interpretation across laboratories have led to significant variability, limiting comparability between studies and vaccines and hindering the establishment of robust correlates of protection. This reprint provides a systematic and up-to-date overview of advances in SARS-CoV-2 neutralization assay development and vaccine evaluation. By summarizing methodological progress and remaining challenges, it aims to serve as a reference for researchers, clinicians, regulatory scientists, and public health professionals involved in COVID-19 research and response. 2026-04-16T20:30:27Z 2026-04-16T20:30:27Z 2026 book ONIX_20260416T142754_9783725865345_24 9783725865345 9783725865352 https://directory.doabooks.org/handle/20.500.12854/175369 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/ https://mdpi.com/books/pdfview/book/12284 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-7258-6535-2 10.3390/books978-3-7258-6535-2 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783725865345 9783725865352 194 CH open access |
| spellingShingle | SARS-CoV-2 Neutralising antibodies Point-of-care diagnostic test Antiviral Monoclonal antibody Cytokine blockers Correlates of protection Antibody dynamics Antibody kinetics Anti-SARS-CoV-2 antibodies Longitudinal assessment Serological immune response Humoral response post-vaccination Vaccination breakthrough Side effects Vaccination strategy COVID-19 Omicron Breakthrough infection Booster vaccination Primary vaccination Spike Standardization LC–MS Vaccine SARS-CoV-2 pseudovirus Mouse model In vivo bioluminescent DNA vaccine Epitope mapping Microarray Neutralizing antibodies Inactivated vaccines Delta Immunogenicity Adjuvants Bivalent vaccination Neutralization Assay Surrogate Antibodies High-content screening Variants Clinical trials Standards Correlation of protection N A thema EDItEUR::M Medicine and Nursing Detection of SARS-CoV-2 Neutralizing Antibodies and Vaccine Development |
| title | Detection of SARS-CoV-2 Neutralizing Antibodies and Vaccine Development |
| title_full | Detection of SARS-CoV-2 Neutralizing Antibodies and Vaccine Development |
| title_fullStr | Detection of SARS-CoV-2 Neutralizing Antibodies and Vaccine Development |
| title_full_unstemmed | Detection of SARS-CoV-2 Neutralizing Antibodies and Vaccine Development |
| title_short | Detection of SARS-CoV-2 Neutralizing Antibodies and Vaccine Development |
| title_sort | detection of sars cov 2 neutralizing antibodies and vaccine development |
| topic | SARS-CoV-2 Neutralising antibodies Point-of-care diagnostic test Antiviral Monoclonal antibody Cytokine blockers Correlates of protection Antibody dynamics Antibody kinetics Anti-SARS-CoV-2 antibodies Longitudinal assessment Serological immune response Humoral response post-vaccination Vaccination breakthrough Side effects Vaccination strategy COVID-19 Omicron Breakthrough infection Booster vaccination Primary vaccination Spike Standardization LC–MS Vaccine SARS-CoV-2 pseudovirus Mouse model In vivo bioluminescent DNA vaccine Epitope mapping Microarray Neutralizing antibodies Inactivated vaccines Delta Immunogenicity Adjuvants Bivalent vaccination Neutralization Assay Surrogate Antibodies High-content screening Variants Clinical trials Standards Correlation of protection N A thema EDItEUR::M Medicine and Nursing |
| topic_facet | SARS-CoV-2 Neutralising antibodies Point-of-care diagnostic test Antiviral Monoclonal antibody Cytokine blockers Correlates of protection Antibody dynamics Antibody kinetics Anti-SARS-CoV-2 antibodies Longitudinal assessment Serological immune response Humoral response post-vaccination Vaccination breakthrough Side effects Vaccination strategy COVID-19 Omicron Breakthrough infection Booster vaccination Primary vaccination Spike Standardization LC–MS Vaccine SARS-CoV-2 pseudovirus Mouse model In vivo bioluminescent DNA vaccine Epitope mapping Microarray Neutralizing antibodies Inactivated vaccines Delta Immunogenicity Adjuvants Bivalent vaccination Neutralization Assay Surrogate Antibodies High-content screening Variants Clinical trials Standards Correlation of protection N A thema EDItEUR::M Medicine and Nursing |
| url | ONIX_20260416T142754_9783725865345_24 |